
Charles E Leonard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4833966/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Angiotensinâ€Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical Pharmacology and Therapeutics, 2022, 111, 218-226.	2.3	6
2	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Annals of Internal Medicine, 2022, 175, 20-28.	2.0	31
3	Research and scholarly methods: Propensity scores. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 467-475.	0.5	5
4	Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes Care, 2022, 45, 919-927.	4.3	11
5	Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study. CNS Drugs, 2022, 36, 389-400.	2.7	4
6	Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals. Frontiers in Pharmacology, 2022, 13, .	1.6	4
7	Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury. Journal of Psychiatric Research, 2022, 151, 299-303.	1.5	1
8	Skeletal muscle relaxant drug–drug–drug interactions and unintentional traumatic injury: Screening to detect threeâ€way drug interaction signals. British Journal of Clinical Pharmacology, 2022, 88, 4773-4783.	1.1	3
9	Rate of major bleeding with ibrutinib versus bendamustineâ€rituximab in chronic lymphocytic leukemia: A populationâ€based cohort study. American Journal of Hematology, 2022, 97, .	2.0	2
10	Preoperative Sedative-hypnotic Medication Use and Adverse Postoperative Outcomes. Annals of Surgery, 2021, 274, e108-e114.	2.1	11
11	Populationâ€Based Signals of Antidepressant Drug Interactions Associated With Unintentional Traumatic Injury. Clinical Pharmacology and Therapeutics, 2021, 110, 409-423.	2.3	6
12	Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis. Muscle and Nerve, 2021, 64, 156-162.	1.0	5
13	Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less. Endocrinology, Diabetes and Metabolism, 2021, 4, e00245.	1.0	2
14	Validity of <scp>ICDâ€10â€CM</scp> diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. Pharmacoepidemiology and Drug Safety, 2021, 30, 899-909.	0.9	11
15	Spotlight commentary: A role for realâ€world evidence to inform the clinical care of patients with diabetes mellitus. British Journal of Clinical Pharmacology, 2021, 87, 4549-4551.	1.1	1
16	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.3	3
17	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 910-919.	2.0	25
18	Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs. Biomedicine and Pharmacotherapy, 2021, 139, 111559.	2.5	2

#	Article	IF	CITATIONS
19	Comparative Safety of Dipeptidyl Peptidaseâ€4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Populationâ€Based Cohort Studies. Clinical Pharmacology and Therapeutics, 2021, , .	2.3	3
20	Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues. JAMA Network Open, 2021, 4, e2124443.	2.8	2
21	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. American Heart Journal, 2021, 242, 71-81.	1.2	0
22	Investigation of Concomitant Use of Alzheimer's Disease Drugs with Sulfonylureas and Serious Hypoglycemia. Epidemiology, 2021, 32, e3-e5.	1.2	0
23	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.3	1
24	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012). Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	1
25	The Selfâ€Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions. Clinical Pharmacology and Therapeutics, 2020, 107, 321-322.	2.3	2
26	Twelveâ€year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes, Obesity and Metabolism, 2020, 22, 705-710.	2.2	3
27	Risk of Nonunion with Nonselective NSAIDs, COX-2 Inhibitors, and Opioids. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1230-1238.	1.4	31
28	Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomedicine and Pharmacotherapy, 2020, 130, 110531.	2.5	17
29	Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016. JAMA Network Open, 2020, 3, e207664.	2.8	28
30	Impact of Hospitalization and Medication Switching on Postâ€discharge Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation. Pharmacotherapy, 2020, 40, 1022-1035.	1.2	6
31	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. Journal of Substance Abuse Treatment, 2020, 119, 108141.	1.5	3
32	Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Selfâ€Controlled Case Series Study. Clinical Pharmacology and Therapeutics, 2020, 108, 1010-1017.	2.3	4
33	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. Scientific Reports, 2020, 10, 10070.	1.6	6
34	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Substance Abuse: Research and Treatment, 2020, 14, 117822181989458.	0.5	1
35	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular Diabetology, 2020, 19, 25.	2.7	16
36	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis and Rheumatology, 2020, 72, 1067-1071.	2.9	13

#	Article	IF	CITATIONS
37	Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions Leading to Thromboembolic Events. Clinical Pharmacology and Therapeutics, 2020, 108, 377-386.	2.3	8
38	Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol. JMIR Research Protocols, 2020, 9, e21811.	0.5	2
39	Does hospitalization for thromboembolism improve oral anticoagulant adherence in patients with atrial fibrillation?. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 986-992.e2.	0.7	1
40	Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin. Clinical Pharmacology and Therapeutics, 2019, 105, 210-218.	2.3	17
41	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. Pharmaceutical Medicine, 2019, 33, 29-43.	1.0	4
42	Clopidogrel Drug Interactions and Serious Bleeding: Generating Realâ€World Evidence via Automated Highâ€Throughput Pharmacoepidemiologic Screening. Clinical Pharmacology and Therapeutics, 2019, 106, 1067-1075.	2.3	12
43	Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study. Scientific Reports, 2019, 9, 4685.	1.6	7
44	Outdoor temperature and survival benefit of empiric potassium in users of furosemide in US Medicaid enrollees: a cohort study. BMJ Open, 2019, 9, e023809.	0.8	1
45	Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Safety, 2019, 42, 515-527.	1.4	12
46	Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care, 2018, 41, 713-722.	4.3	26
47	The Authors Respond. Epidemiology, 2018, 29, e8-e9.	1.2	1
48	Chart validation of inpatient <scp>ICDâ€9â€CM</scp> administrative diagnosis codes for acute myocardial infarction (<scp>AMI</scp>) among intravenous immune globulin (<scp>IGIV</scp>) users in the <scp>S</scp> entinel <scp>D</scp> istributed <scp>D</scp> atabase. Pharmacoepidemiology and Drug Safety, 2018, 27, 398-404.	0.9	18
49	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drugâ€outcome associations: The case of clindamycin and <i>Clostridium difficile</i> infection. Pharmacoepidemiology and Drug Safety, 2018, 27, 731-739.	0.9	6
50	Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiology and Drug Safety, 2018, 27, 9-18.	0.9	50
51	Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study. PLoS ONE, 2018, 13, e0193800.	1.1	7
52	Biomedical Informatics Approaches to Identifying Drug–Drug Interactions. Epidemiology, 2017, 28, 459-468.	1.2	22
53	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends in Endocrinology and Metabolism, 2017, 28, 561-586.	3.1	31
54	The Trend-in-trend Research Design for Causal Inference. Epidemiology, 2017, 28, 529-536.	1.2	16

#	Article	IF	CITATIONS
55	Lost in Translation: No Effect of a Highâ€Profile Publication on the Concomitant Use of Interacting Drugs. Clinical and Translational Science, 2017, 10, 426-430.	1.5	0
56	Sentinel Modular Program for Propensity Score–Matched Cohort Analyses. Epidemiology, 2017, 28, 838-846.	1.2	32
57	The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Services Research, 2017, 17, 304.	0.9	27
58	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. International Journal of Cardiology, 2017, 228, 761-770.	0.8	21
59	Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Scientific Reports, 2017, 7, 18037.	1.6	4
60	Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Research and Clinical Practice, 2016, 115, 60-67.	1.1	6
61	Challenges in recruiting subjects to a pilot trial of patient-managed in-hospital insulin. BMC Research Notes, 2015, 8, 523.	0.6	1
62	Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors. Stroke, 2015, 46, 722-731.	1.0	25
63	Comment on: "Desideratum for Evidence-Based Epidemiology― Drug Safety, 2015, 38, 101-103.	1.4	5
64	Empiric Potassium Supplementation and Increased Survival in Users of Loop Diuretics. PLoS ONE, 2014, 9, e102279.	1.1	13
65	Proton pump inhibitors and traditional nonsteroidal antiâ€inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiology and Drug Safety, 2012, 21, 1155-1172.	0.9	74
66	Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety, 2012, 21, 331-332.	0.9	4
67	Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually Eligible Medicaid-Medicare Beneficiaries of Five States. Journal of Clinical & Experimental Cardiology, 2012, 01, 1-9.	0.0	33
68	Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety, 2011, 20, 903-913.	0.9	91
69	Validation of diagnostic codes for outpatientâ€originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiology and Drug Safety, 2010, 19, 555-562.	0.9	109
70	Response to commentary entitled â€~Commentary on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy <i>et al</i> . and Chung <i>et al</i> .'. Pharmacoepidemiology and Drug Safety, 2010, 19, 576-576.	0.9	3
71	A System for De-identifying Medical Message Board Text. , 2010, , .		2
72	CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity. Journal of Clinical Pharmacology, 2009, 49, 1483-1487.	1.0	20

#	Article	IF	CITATIONS
73	Patient Reported Receipt of Medication Instructions for Warfarin is Associated with Reduced Risk of Serious Bleeding Events. Journal of General Internal Medicine, 2008, 23, 1589-1594.	1.3	33
74	Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2008, 17, 1131-1136.	0.9	23
75	Cisapride and ventricular arrhythmia. British Journal of Clinical Pharmacology, 2008, 66, 375-385.	1.1	47
76	Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. Journal of Clinical Epidemiology, 2008, 61, 561-571.	2.4	29
77	Instantaneous preference was a stronger instrumental variable than 3- and 6-month prescribing preference for NSAIDs. Journal of Clinical Epidemiology, 2008, 61, 1285-1288.	2.4	22
78	Researchers and HIPAA. Epidemiology, 2007, 18, 518.	1.2	13
79	Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS). Medical Care, 2007, 45, 1216-1220.	1.1	63
80	New-onset cancer cases in FDA's Sentinel System: a large distributed system of US electronic healthcare data. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	0